Potential Novel Therapeutic Strategies in Cystic Fibrosis: Antimicrobial and Anti-Biofilm Activity of Natural and Designed α-Helical Peptides Against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia

2014 ◽  
pp. 33-58
Keyword(s):  
Cystic Fibrosis ◽  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Stenotrophomonas Maltophilia ◽  
Therapeutic Strategies ◽  
Helical Peptides ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Potential Novel Therapeutic Strategies in Cystic Fibrosis

2014 ◽  
pp. 1-25
Author(s):  
Arianna Pompilio ◽  
Valentina Crocetta ◽  
Marco Scocch ◽  
Stefano Pomponio ◽  
Valentina Di Vincenzo ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Therapeutic Strategies ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Novel therapeutic strategies for treating Pseudomonas aeruginosa infection

2020 ◽  
Vol 15 (12) ◽  
pp. 1403-1423
Author(s):  
Xiaolong Shao ◽  
Yingpeng Xie ◽  
Yingchao Zhang ◽  
Jingui Liu ◽  
Yiqing Ding ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Therapeutic Strategies ◽  
Pseudomonas Aeruginosa Infection ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol

2018 ◽  
Vol 19 (2) ◽  
pp. 165-176 ◽  
Author(s):  
Yan Wang ◽  
Zhao-Peng Liu
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Maximum Tolerated Dose ◽  
Therapeutic Strategies ◽  
Low Density ◽  
Pcsk9 Inhibitors ◽  
Cvd Risk ◽  
Safety Issues ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Statins are currently the major therapeutic strategies to lower low-density lipoprotein cholesterol (LDL-C) levels. However, a number of hypercholesterolemia patients still have a residual cardiovascular disease (CVD) risk despite taking the maximum-tolerated dose of statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lipoprotein receptor (LDLR), inducing its degradation in the lysosome and inhibiting LDLR recirculating to the cell membranes. The gain-offunction mutations in PCSK9 elevate the LDL-C levels in plasma. Therefore, PCSK9 inhibitors become novel therapeutic approaches in the treatment of hypercholesterolemia. Several PCSK9 inhibitors have been under investigation, and much progress has been made in clinical trials, especially for monoclonal antibodies (MoAbs). Two MoAbs, evolocumab and alirocumab, are now in clinical use. In this review, we summarize the development of PCSK9 inhibitors, including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), small molecule inhibitor, MoAbs, mimetic peptides and adnectins, and the related safety issues.

Sign in / Sign up

Export Citation Format

Share Document